Clinical Trial Search

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: Treatment-related Mortality Within 30 Days (TRM30) — 0 Participants

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants

Primary: Number of Patients With Objective Response — 10; 8 participants

Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects

Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 3; 1; 0; 0 Participants

Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Objective Response Rate — 18.8; 33.3; 30.0 Percentage of Patients

Primary: Maximum Tolerated Dose — 1.8; 1.5 mg/m^2 of Bortezomib

Primary: Clinical Response Rate — 2; 0; 1; 1 participants

Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: Progression Free Survival — 389; 334 days — p=0.039

Primary: Objective Response Rate — 3 Participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS) — 24.5 percentage of participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Maximum Tolerated Dose of Lenalidomide When Given With Obinutuzumab Defined as the Highest Dose Level Have Been Treated With Less Than 2 Instances of Dose Limiting…

Primary: 3 Years Event-free Survival — 51; 56; 126; 123 Participants

Primary: Overall Response Rate — 12 Participants — p=0.044

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Overall Response Rate — 40; 55; 29 percentage of patients

Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…

Primary: Progression-free Survival at 1 Year — 38 percentage of participants

Primary: Overall Response Rate — 53.3; 76.1 percentage of participants — p=0.29

Primary: Response Rate to Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphoma With Rituximab Resistance — 14; 13 Participants